From developmental disorder to heritable cancer: It's all in the BMP/TGF-β family

Nature Reviews Genetics

Volumn 4, Issue 10, 2003, Pages 763-773

  Waite, Kristin A ^a   Eng, Charis ^a,b,c  

^a OHIO STATE UNIVERSITY   (United States)

^b OHIO STATE UNIVERSITY   (United States)

^c UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BONE MORPHOGENETIC PROTEIN; PHOSPHATASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; TRANSFORMING GROWTH FACTOR BETA;

CANCER; COWDEN SYNDROME; DEVELOPMENTAL DISORDER; GASTROINTESTINAL DISEASE; GASTROINTESTINAL TUMOR; GENE MUTATION; GENETIC LINKAGE; HERITABILITY; HUMAN; INHERITANCE; NONHUMAN; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION;

ANIMALS; BONE DISEASES, DEVELOPMENTAL; BONE MORPHOGENETIC PROTEINS; HUMANS; MUTATION; NEOPLASMS; TRANSFORMING GROWTH FACTOR BETA;

EID: 0141594935     PISSN: 14710056     EISSN: None     Source Type: Journal    
DOI: 10.1038/nrg1178     Document Type: Review

References (89)

1. Markowitz, S. et al. Inactivation of the type II TGF-B receptor in colon cancer cells with microsatellite instanity, Science 268, 1336-1338 (1995)
2. Teicher, B. A Malignant cells, directors of the malignant process: role of transforming growth factor-β. Cancer Met. Rey. 20, 133-143 (2001).
3. Miyazono, K. TGF-B/SMAD signaling and its involvement in tumor progression. Biol. Pharm. Bull. 23, 1125-1130 (2000).
4. Miyazono, K. TGF-B signaling by Smad proteins. Cytokine Growth Fact. Rev. 11, 15-22 (2000).
5. Zimmerman, C. M. & Padgett, R. W. Transforming growth factor-β signaling mediators and modulators. Gene 249, 17-30 (2000).
6. Derynck, R., Akhurst, R. J. & Balmain, A. TGF-β signaling in tumor suppression and cancer progression. Nature Genet. 29, 117-129 (2001).
7. Shi, Y. & Massague, J. Mechanisms of TGF-β signaling: from cell membrane to the nucleus. Cell 113, 685-700 (2003).
8. Nichols, W. C. et al. Localization of the gene for familial primary pulmonary hypertension to chromosome 2q31-q33. Nature Genet. 15, 277-280 (1997).
9. Morse, J. H. et al. Mapping of familial primary pulmonary hypertension locus (PPH1) to chromosome 2q31-q32. Circulation 95, 2603-2606 (1997).
10. Machado, R. D. et al. A physical and transcnpt map based upon refinement of the critical interval for PPH1, a gene for familial primary pulmonary hypertension. Genomics 68, 220-228 (2000).
11. International PPH Consortium. Heterozygous germline mutations in BMPR2, encoding a TGFβ receptor, cause familial primary pulmonary hypertension. Nature Genet. 26, 81-84 (2000). This study identifies BMPR2 as the susceptibility gene for familial primary pulmonary hypertension.
12. Deng, Z. et al. Familial primary pulmonary hypertension (gene PPH1) is caused by mutations in the bone morphogenetic protein receptor-II gene. Am. J. Hum. Genet. 67, 737-744 (2000).
13. Machado, R. D. et al. BMPR2 hapicinsufficiency as the inherited molecular mechanism for primary pulmonary hypertension. Am. J. Hum. Genet. 68, 92-102 (2001)
14. Thomson. J. R. et al. Sporadic primary pulmonary hypertension is associated with germline mutations of the gene encoding BMPR-II, a receptor member of the TGF-B family. J. Med. Genet. 37, 741-745 (2000). This paper reports that ∼25% of apparently sporadic cases of primary pulmonary hypertension carry unsuspected germline mutations in BMPR2.
15. Eng, C. et al. The relationship between specific RET proto-oncogene mutations and disease phenotype in multiple endocnne neoplasia type 2: International RET Mutation Consortium analysis. JAMA 276, 1575-1579 (1996).
16. Dora, H., Vukecevic, S. & Sampath, T. K. Bone morphogenetic protein-7 (Op-1) inhibits smooth muscle cell proliferation and stimulates the expression of markers that are characteristic of SMC phenotype in vitro. J. Cell. Physiol. 184, 37-45 (2000).
17. Nakaoka, T. et al. Inhibition of rat vascular smooth muscle proliferation in vitro and in vivo by morphogenetic protein-2. J. Clin Invest. 100, 2824-2832 (1997).
18. Morrell, N W. et al. Altered growth responses of pulmonary artery smooth muscle cells from patients with primary pulmonary hypertension to transforming growth factor-B1 and bone morphogenetic proteins. Circulation 104, 790-795 (2001).
19. Atkinson, C. et al. Primary pulmonary hypertension is associated with reduced pulmonary vascular expression of type II bone morphogenetic protein receptor. Circulation 105, 1672-1678 (2002).
20. Rudarakanchana, N. et al. Functional analysis of bone morphogenetic protein type II receptor mutations underlying primary pulmonary hypertension. Hum. Mol. Genet. 11, 1517-1525 (2002).
21. Nishihara, A., Watabe, T, Imamura, T. & Miyazono, K. Functional heterogeneity of bone morphogenetic protein receptor-II mutants found in patients with primary pulmonary hypertension. Mol. Biol. Cell 13, 3055-3063 (2002).
22. Massague, J. How cells read TGF-β signals. Nature Rev. Mol. Cell. Biol. 1, 169-178 (2000).
23. Roberts, A. B. The ever-increasing complexity of TGF-β signaling. Cytokine Growth Fact. Rev. 13, 3-5 (2002).
24. Eng, C. To be or not to BMP. Nature Genet. 28, 105-107 (2001).
25. Eddahibi, S. et al. Serotonin transporter overexpression is responsible for pulmonary artery smooth muscle hyperplasia in primary pulmonary hypertension. J. Clin. Invest. 108, 1141-1150 (2001).
26. Porteus, M. E. M., Burn, J. & Proctor, S Hereditary haemorrhagic telangeictasia: a clinical analysis. J. Med. Genet. 29, 527-530 (1992).
27. Guttmacher, A. E., Marchuk, D. A. & White, R I. Hereditary hemorrhagic telangiectasia. N. Engl. J. Med. 333, 918-924 (1995).
28. White, R. I. & Pollak, J. S. Pulmonary arteriovenous malformations: options for management. Ann. Thorac. Surg. 57, 519-521 (1994).
29. Shovlin, C. L. et al. A gene for hereditary haemorrhagic telangiectasia maps to chromosome 9q. Nature Genet. 6, 205-209 (1994).
30. Vincent, P. et al. A third locus for hereditary haemorrhagic telangiectasia maps to chromosome 12q. Hum. Mol. Genet. 4, 945-949 (1995).
31. Johnson, D. W. et al. A second locus for hereditary haemorrhagic telangiectasia maps to chromosome 12. Genome Res 5, 21-28 (1995).
32. McAllister, K. A. et al. Endoglin, a TGF-β binding protein of endothelial cells, is the gene for hereditary haemorrhagic telangiectasia type 1 Nature Genet. 8, 345-351 (1994). This study identifies ENG-encoding endoglin as a susceptibility gene for hereditary haemorrhagic telangiectasia.
33. Johnson, D. W. et al. Mutations in the activin receptor-like kinase 1 gene in hereditary haemorrhagic telangiectasia type 2. Nature Genet. 13, 189-196 (1996). In this study, ALK1 (ACVRL1) is identified as a second susceptibility gene for hereditary haemorrhagic telangiectasia.
34. Shovlin, C. L., Hughes, J. M. B., Scott, J., Seidman, C. E. & Seidman, J. G. Characterization of endoglin and identification of novel mutations in hereditary hemorrhagic telangiectasia. Am J. Hum. Genet. 61, 68-79 (1997).
35. Berg, J. N., Guttmacher, A. E., Marchuk, D. A. & Porteous, M. E. M. Clinical heterogeneity in hereditary haemorrhagic telangiectasia - are pulmonary arteriovenous malformations more common in families linked to endoglin? J. Med. Genet. 33, 256-257 (1996).
36. Dakeishl, M. et al. Genetic epidemiology of hereditary hemorrhagic telangiectasia in a local community in the northern part of Japan. Hum. Mutat. 19, 140-148 (2002).
37. Gallione, C. J. et al. Two common endoglin mutations in families with hereditary hemorrhagic telangiectasia in the Netherlands Antilles: evidence for a founder effect. Hum. Genet. 107, 40-44 (2000).
38. Berg, J. N et al. The activin receptor-like kinase 1 gene: genomic structure and mutations in hereditary hemorrhagic telangiectasia type 2. Am. J. Hum. Genet. 61, 60-67 (1997).
39. Abdalla, S. A., Cymerman, U., Johnson, R. M., Deber, C. M. & Letarte, M. Disease-associated mutations in conserved residues of ALK-1 kinase domain. Eur. J. Hum. Genet. 11, 279-287 (2003).
40. Hanks, S. K., Quinn, A. M. & Hunter, T. The protein kinase family: conserved features and deduced phylogeny of the catalytic domain. Science 241, 42-52 (1988).
41. Garamszegi, N. et al. Transforming growth factor-β receptor signaling and endocytosis are linked through a COOH terminal activation motif in the type 1 receptor. Mol. Biol. Cell 12, 2881-2893 (2001).
42. Guerreoro-Esteo, M., Sanchez-Elsner, T., Letamendia, A. & Bemabeu, C. Extracellular and cytoplasmic domains of endoglin interact with the transforming growth factor-β receptors I and II. J. Biol. Chem. 277, 29197-29209 (2002).
43. Lastres, P. et al. Endoglin modulates cellular responses to TGF-β1. J. Cell. Biol. 133, 1109-1121 (1996).
44. Barbara, N. P., Wrana, J. L. & Letarte, M. Endoglin is an accessory protein that interacts with the signaling receptor complex of multiple members of the transforming growth factor B superfamily. J. Biol. Chem. 274, 584-594 (1999).
45. Pece, S. et al. Mutant endoglin in hereditary hemorrhagic telangiectasia type 1 is transiently expressed intracellularly and is not a dominant negative. J. Clin. Invest. 100, 2568-2579 (1997).
46. Raab, U. et al. Expression of normal and truncated forms of human endoglin. Biochem. J. 339, 579-588 (1999).
47. Lux, A., Gallione, C. J. & Marchuk, D. A. Expression analysis of endoglin missense and truncation mutations: insights into protein structure and disease mechanisms. Hum. Mol. Genet. 22, 745-755 (2000).
48. Paquet, M. E. et al. Analysis of several endoglin mutants reveals no endogenous mature or secreted protein capable of interfering with normal endoglin function. Hum. Mol. Genet. 10, 1347-1357 (2001).
49. Bourdeau, A. Dumont, D. J. & Letarte, M. A. A murine model of hereditary hemorrhagic telangiectasia. J. Clin. Invest. 104, 1343-1351 (1999).
50. Bourdeau, A. et al. Potential role of modifier genes influencing transforming growth factor-B1 levels in the development of vascular defects in endoglin heterozygous mice with hereditary hemorrhagic telangiectasia. Am. J. Pathol. 158, 2011-2020 (2001).
51. Santomi, J. et al. Cerebral vascular abnormalities in a murine model for hereditary hemorrhagic telangiectasia. Stroke 34, 783-789 (2003).
52. Fanning, A. S. & Anderson, J. M. Protein modules as organizers of membrane structure. Curr. Opin. Cell Biol. 432-439 (1999).
53. Kay B. K., Williamson, M. P. & Sudol, M. The importance of being proline: the interaction of proline-rich motifs in signaling proteins with their cognate domains. FASEB J. 14, 231-241 (2000).
54. Howe, J. R. et al. Mutations in the SMAD4/DPC4 gene in juvenile polyposis Science 280, 1086-1088 (1998). This study identifies MADH4 as a susceptibility gene for a subset of families with juvenile polyposis syndrome.
55. Howe, J. R. et al. Germline mutations of BMPR1A in juvenile polyposis. Nature Genet. 28, 184-187 (2001). In this study, BMPR1A germline mutations are identified in MADH4-mutation negative probands with familial juvenile polyposis syndrome.
56. Zhou, X. P. et al. Germline mutations in BMPR1A/ALK3 cause a subset of juvenile polyposis syndrome and of Cowden and Bannayan-Riley-Ruvalcaba syndromes. Am. J. Hum. Genet. 69, 704-711 (2001). This paper reports that germline BMPR1A mutations cause sporadic juvenile polyposis syndrome as well as rare Cowden syndrome probands.
57. Eng, C. & Blackstone, M. O. Peutz-Jeghers syndrome Med. Rounde 1, 165-171 (1988).
58. Jarvinen, J. & Franssila, K. O. Familial juvenile polyposis coli: increased risk of colorectal cancer. Gut 25, 792-800 (1984).
59. Coburn, M. C., Pricolo, V. E., DeLuca, F. G. & Bland, K. I. Malignant potential in intestinal juvenile polyposis syndromes. Ann. Surg. Oncol. 2, 386-391, (1995).
60. Howe, J. R. Mitros, F. A. & Summers, R. W. The risk of gastrointestinal carcinoma in familial juvenile polyposis. Ann. Surg. Oncol. 5, 751-756 (1998).
61. Hofting, I., Pott, G. & Stolte, M. Das syndrom der juvenilen polyposis. Leber Magen. Darm. 23, 107-108 (1993).
62. Howe, J. R. et al. Common deletion of SMAD4 in juvenile palyposis is a mutational hotspot. Am. J. Hum. Genet. 70, 1357-1362 (2002).
63. Friedl, W. et al. Juvenile polyposis: massive gastric polyposis is more common in MADH4 mutation carriers than in BMPR1A mutation carriers. Hum. Genet. 111, 108-111 (2002). This study shows that MADH4-mutation positive juvenile polyposis probands are at increased risk of giant gastric polyps compared with those that have BMPR1A mutations.
64. Sayed, M. G. et al. Germline SMAD4 or BMPR1A mutations and phenotype in juvenile polyposis. Ann. Surg. Oncol. 9, 901-906 (2002).
65. Shi, Y., Hata, A., Lo, R. S., Massague, J. & Pavletich, N. P. A structural basis for the mutational inactivation of the tumor suppressor Smad4. Nature 388, 87-93 (1997).
66. Kawabata, M., Inoue, H., Hanyu, A., Imamura, T. & Miyazono, K. SMAD proteins exist as monomers in vivo and undergo homo- and hetero-oligomensation upon activation by serine/threonine kinase receptors. EMBO J. 17, 4056-4065 (1998).
67. Bevan, S. et al. Screening SMAD1, SMAD2, SMAD3 and SMAD5 for germline mutations in juvenile polyposis syndrome Gut 45, 406-408 (1999).
68. Olschwang, S., Serova-Sinilnikova, O. M., Lenoir, G. M. & Thomas, G. PTEN germline mutations in juvenile polyposis coli. Nature Genet. 18, 12-14 (1998).
69. Eng, C. & Ji, H. Molecular classification of the inherited hamartoma polyposis syndromes: clearing the muddied waters. Am. J. Hum. Genet. 62, 1020-1022 (1998).
70. Kurose, K., Araki, T. Matsunaka, T. Takada, Y. & Emi, M. Variant manifestation of Cowden disease in Japan: hamartomatous polyposis of the digestive tract with mutation of the PTEN gene. Am. J. Hum. Genet. 64, 308-310 (1999).
71. Eng, C. Will the real Cowden syndrome please stand up: revised diagnostic critena. J. Med. Genet. 37, 828-830 (2000).
72. Waite, K. A. & Eng, C. BMP2 exposure results in decreased PTEN protein degradation leading to increased PTEN levels. Hum. Mol. Genet. 12, 679-684 (2003). This study shows that BMP decreases PTEN protein degradation, which results in increased PTEN levels. Therefore, by implication, BMP signalling can result in apoptosis that is mediated by PTEN.
73. Trembath, R. C. et al. Clinical and molecular genetic features of pulmonary hypertension in patients with hereditary hemorrhagic telangiectasia. N. Engl. J. Med 345, 325-334 (2001).
74. Blanquet, V., Créau-Goldberg, N., de Grouchy, J. & Tudeau, C. Molecular detection of constitutional deletions in patients with retinoblastoma. Am. J Med. Genet 39, 355-361 (1991).
75. Blanquet, V. et al. Spectrum of germline mutations in the RB1 gene: a study of 232 patients with hereditary and non hereditary retinoblastoma. Hum. Mol. Genet. 4, 383-388 (1995).
76. Stolle, C. et al. Improved detection of germline mutations in the von Hippel-Lindau disease tumor suppressor gene. Hum. Mutat. 12, 417-423 (1998).
77. Zhou, X. P. et al. Germline PTEN promoter mutations and deletions in Cowden/Bannayan-Riley-Ruvalcaba syndrome result in aberrant PTEN protein and dysregulation of the phosphoinositol-3-kinase/Akt pathway. Am. J. Hum. Genet. (in the press).
78. Abraham, W. T. et al. Angiotensin-converting enzyme DD genotype in patients with primary pulmonary hypertension: increased frequency and association with preserved haemodynamics. J. Renin Angiotens. Aldoster. Sys. 4, 27-30 (2003).
79. Weber, H. C., Marsh, D. Lubensky, I., Lin, A. & Eng, C. Germline PTEN/MMAC1/TEP1 mutations and association with gastrointestinal manifestations in Cowden disease. Gastroenterology 114, 2902 (1998).
80. Hemminki, A. et al. Localisation of a susceptibility locus for Peutz-Jeghers syndrome to 19p using comparative genomic hybridization and targeted linkage analysis. Nature Genet. 15, 87-90 (1997).
81. Hemminki, A. et al. A serine/threonine kinase gene defective in Peutz-Jeghers syndrome. Nature 391, 184-187 (1998).
82. Jenne, D. E. et al. Peutz-Jeghers syndrome is caused by mutations in a novel serine threonine kinase. Nature Genet. 18, 38-44 (1998).
83. Mehenni, H. et al. Peutz-Jeghers syndrome: confirmation of linkage to chromosome 19p13.3 and identification of a potential second locus on 19q13.4. Am. J. Hum. Genet 61, 1327-1334 (1997).
84. Liaw, D. et al. Germline mutations of the PTEN gene in Cowden disease, an inherited breast and thyroid cancer syndrome. Nature Genet. 16, 64-67 (1997).
85. Marsh, D. J. et al. Mutation spectrum and genotype-phenotype analyses in Cowden disease and Bannayan-Zonana syndrome, two hamartoma syndromes with germline PTEN mutation. Hum. Mol. Genet. 7, 507-515 (1998).
86. Marsh, D. J. et al. Germline mutations in PTEN are present in Bannayan-Zonana syndrome. Nature Genet. 16, 333-334 (1997).
87. Marsh, D. J. et al. PTEN mutation spectrum and genotype-phenotype correlations in Bannayan-Riley-Ruvalcaba syndrome suggest a single entity with Cowden syndrome. Hum. Mol. Genet. 8, 1461-1472 (1999).
88. Jaeger, E. E. M. et al. An ancestral Ashkenazi hapiotype at the HMPS/CRAC1 locus on 15q13-q14 is associated with hereditary mixed polyposis syndrome. Am. J. Hum. Genet. 72, 1261-1267 (2003).
89. van den Driesche, S., Mummery, C. L. & Westermann, C. J. Hereditary hemorrhagic telangiectasia: an update on transforming growth factor-β signaling in vasculogenesis and angiogenesis. Cardiovasc. Res. 58, 20-31 (2003).